Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
IPO Year: 2009
Exchange: NASDAQ
Website: cumberlandpharma.com
Date | Price Target | Rating | Analyst |
---|
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
ARS - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
– New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity.
NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cumberland is completing the FIGHT DMD™ trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year.
– Real World Study Compared Over 150,000 Adult & Pediatric Patients –– Caldolor Associated with Fewer Adverse Drug Reactions –– Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:CPIX) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse d
NASHVILLE, Tenn., Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024. A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384. Once registered, participants can dial in from their phone using a dial-in and PIN
NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. Highlights include: $9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024.Adjusted earnings of $0.2 million, which represents a $0.8 million improvement over the prior period in 2024.$78.5 million in assets, $52.5 million in liabilities and $26.3 m
NASHVILLE, Tenn., July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024. A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e. Once registered, participants can dial in from their phone using a dial-in and PIN
NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders' equity. "It has been a steady start to 2024 – and despite some challenges the biopharmaceutical sector is facing in the financial markets amid stubborn inflation and stalled intere
NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024. A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIbb2d35bc9570474dabf8b2e3d2e4ca72. Once registered, participants can dial in from their phone using a dial-in and PIN nu
Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn., April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants. The report, published in Anesthesiology News, General Surge
2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn., March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations. Cumberland ended the year with $82 million in total assets – including $18 million in cash, $53 million in liabilities and $30 million of shareholders' equity. "In many ways 2023 was a building year for
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka. Brown is an attorney at Adams and Reese LLP, a
– New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity.
NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cumberland is completing the FIGHT DMD™ trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year.
– Real World Study Compared Over 150,000 Adult & Pediatric Patients –– Caldolor Associated with Fewer Adverse Drug Reactions –– Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:CPIX) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse d
NASHVILLE, Tenn., Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024. A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384. Once registered, participants can dial in from their phone using a dial-in and PIN
NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. Highlights include: $9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024.Adjusted earnings of $0.2 million, which represents a $0.8 million improvement over the prior period in 2024.$78.5 million in assets, $52.5 million in liabilities and $26.3 m
NASHVILLE, Tenn., July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024. A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e. Once registered, participants can dial in from their phone using a dial-in and PIN
NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders' equity. "It has been a steady start to 2024 – and despite some challenges the biopharmaceutical sector is facing in the financial markets amid stubborn inflation and stalled intere
NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024. A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIbb2d35bc9570474dabf8b2e3d2e4ca72. Once registered, participants can dial in from their phone using a dial-in and PIN nu
Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn., April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants. The report, published in Anesthesiology News, General Surge
2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn., March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations. Cumberland ended the year with $82 million in total assets – including $18 million in cash, $53 million in liabilities and $30 million of shareholders' equity. "In many ways 2023 was a building year for
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G/A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.05) per share. This is a 145.45 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $8.50 million in sales this quarter. This is a 7.88 percent decrease over sales of $9.22 million the same period last year.
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion. • 2seventy bio (NASDAQ:TSVT) is expected to report quarterly loss at $0.99 per share on revenue of $14.71 million. • CLPS (NASDAQ:CLPS) is expected to report earnings for its first quarter. • Seres Therapeutics (NASDAQ:MCRB) is projected to report quarterly loss at $0.50 per share on revenue of $350 thousand. • Vivid Seats (NASDAQ:SEAT) is expected to report quarterly earnings at $0.06 per share on revenue of $183.67 million. • Nuwellis (N
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. • Ballard Power Systems (NASDAQ:BLDP) is expected to report quarterly loss at $0.13 per share on revenue of $26.20 million. • Melco Resorts and Enter (NASDAQ:MLCO) is likely to report quarterly earnings at $0.03 per share on revenue of $1.03 billion. • Consolidated Comms Hldgs (NASDAQ:CNSL) is expected to report quarterly loss at $0.37 per share on revenue of $274.23 million. • Sophia Genetics (NASDAQ:SOPH) is projected to report quarterly loss at $0.31 per share on revenue of $15.63 million. • Endeavor Gr Hldgs (NYSE:EDR) is estimated to report quarterly earnings
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ® (telavancin) injection in children 2 to 17 years of age. Vibativ is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as well as complicated skin and skin structure infections (cSSSIs) caused by certain gram-positive bacteria in adults2. This is the first reported study evaluating Vibativ in pediatric patients. "Methicillin-resistant Staphylococcus aureus (MRSA) continues to
Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.16 per share. This is a 1700 percent increase over losses of $(0.01) per share from the same period last year. The company reported $10.89 million in sales this quarter. This is a 5.73 percent increase over sales of $10.30 million the same period last year.
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion. • Thoughtworks Holding (NASDAQ:TWKS) is estimated to report quarterly earnings at $0.04 per share on revenue of $301.50 million. • Bioventus (NASDAQ:BVS) is likely to report quarterly earnings at $0.03 per share on revenue of $128.90 million. • Acumen Pharmaceuticals (NASDAQ:ABOS) is estimated to report earnings for its second quarter. • Seres Therapeutics (NASDAQ:MCRB) is projected to report quarterly earnings at $0.55 per share on revenue of $125.50 million. • Xeris Biopharma Holdings (NASDAQ:XERS) is expected to report quarterly lo
-8-K
During Wednesday's session, 212 companies made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was CVS Health (NYSE:CVS). The smallest company by market cap to set a new 52-week low was Biodexa Pharmaceuticals (NASDAQ:BDRX). Biodexa Pharmaceuticals (NASDAQ:BDRX)'s stock made the biggest move downwards, diving 39.16% to reach a new 52-week low. Trio Petroleum (AMEX:TPET)'s stock rebounded the most, as it traded up 0.0% after dropping to a new 52-week low. Here are all the stocks that set new 52-week lows on Wednesday: CVS Health (NYSE:CVS) shares made a new 52-week low of $66.34 on Wednesday. The stoc